M2798135
GNE-3511? , ≥99% , 1496581-76-0
| Pack Size | Price | Stock | Quantity |
| 1mg | RMB820.80 | In Stock |
|
| 5mg | RMB1276.80 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Boiling point: | 579.0±50.0 °C(Predicted) |
| Density | 1.37±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | DMSO:25.63(Max Conc. mg/mL);58.18(Max Conc. mM) Methanol:1.0(Max Conc. mg/mL);2.27(Max Conc. mM) |
| form | A crystalline solid |
| pka | 7.23±0.40(Predicted) |
| color | Light yellow to yellow |
| InChIKey | RHFIAUKMKYHHFA-UHFFFAOYSA-N |
| SMILES | C1(NC2=NC(N3CCC(F)(F)C3)=CC(C3CCN(C4COC4)CC3)=C2)=NC=CC(C#N)=C1 |
Description and Uses
GNE-3511 is a potent and selective dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models. GNE-3511 displays concentration-dependent protection of neurons from degeneration in vitro and demonstrated dose-dependent activity in two different animal models of disease. GNE-3511 displays protection of primary neurons in an in vitro axon degeneration assay as well as activity in the mouse models of glaucoma/optic neuropathy (optic nerve crush) and Parkinson’s disease (MPTP) after oral dosing.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P264-P270-P271-P280-P301+P312-P330-P302+P352-P321-P304+P340-P305+P351+P338-P332+P313-P362+P364-P337+P313-P403+P233-P405-P501 |
| HS Code | 2934999090 |
